CA2787114A1 - Methods of treating meibomian gland dysfunction - Google Patents

Methods of treating meibomian gland dysfunction Download PDF

Info

Publication number
CA2787114A1
CA2787114A1 CA2787114A CA2787114A CA2787114A1 CA 2787114 A1 CA2787114 A1 CA 2787114A1 CA 2787114 A CA2787114 A CA 2787114A CA 2787114 A CA2787114 A CA 2787114A CA 2787114 A1 CA2787114 A1 CA 2787114A1
Authority
CA
Canada
Prior art keywords
compound
halogen
nhcor
subject
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2787114A
Other languages
English (en)
French (fr)
Inventor
James T. Dalton
Jeetendra Eswaraka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncternal Therapeutics Inc
Original Assignee
GTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GTx Inc filed Critical GTx Inc
Publication of CA2787114A1 publication Critical patent/CA2787114A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA2787114A 2010-01-11 2011-01-11 Methods of treating meibomian gland dysfunction Abandoned CA2787114A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29396610P 2010-01-11 2010-01-11
US61/293,966 2010-01-11
PCT/US2011/020871 WO2011085385A1 (en) 2010-01-11 2011-01-11 Methods of treating meibomian gland dysfunction

Publications (1)

Publication Number Publication Date
CA2787114A1 true CA2787114A1 (en) 2011-07-14

Family

ID=44259000

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2787114A Abandoned CA2787114A1 (en) 2010-01-11 2011-01-11 Methods of treating meibomian gland dysfunction

Country Status (10)

Country Link
US (1) US8791158B2 (enExample)
EP (1) EP2523556A4 (enExample)
JP (1) JP2013516501A (enExample)
KR (1) KR20120115380A (enExample)
CN (1) CN103002737A (enExample)
AU (1) AU2011203832A1 (enExample)
CA (1) CA2787114A1 (enExample)
MX (1) MX2012008110A (enExample)
RU (1) RU2012134351A (enExample)
WO (1) WO2011085385A1 (enExample)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8523928B2 (en) 2006-05-15 2013-09-03 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8617229B2 (en) 2006-05-15 2013-12-31 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8628504B2 (en) 2005-07-18 2014-01-14 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction employing fluid jet
US8632578B2 (en) 2006-05-15 2014-01-21 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US8685073B2 (en) 2005-07-18 2014-04-01 Tearscience, Inc. Apparatus for treating meibomian gland dysfunction
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US9216028B2 (en) 2005-07-18 2015-12-22 Tearscience, Inc. Apparatuses for treatment of meibomian glands
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
US9719977B2 (en) 2005-07-18 2017-08-01 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US9913678B2 (en) 2005-07-18 2018-03-13 Tearscience, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
US10842670B2 (en) 2012-08-22 2020-11-24 Johnson & Johnson Vision Care, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
US10940074B2 (en) 2005-07-18 2021-03-09 Tearscience Inc Melting meibomian gland obstructions
US10952896B2 (en) 2006-05-15 2021-03-23 Tearscience Inc Methods and apparatuses for treatment of meibomian gland dysfunction

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007287070C1 (en) * 2006-08-24 2013-02-14 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
US9381183B2 (en) * 2012-07-18 2016-07-05 Physicians Recommended Nutriceuticals, Llc Methods for improving the quality of the meibum composition of meibomian glands
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US12685719B2 (en) 2012-07-13 2026-07-21 University Of Tennessee Research Foundation Treatment of breast cancer with selective androgen receptor modulators and cyclin-dependent kinase 4/6 inhibitors
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
EP3733170A1 (en) 2012-07-13 2020-11-04 Oncternal Therapeutics, Inc. A method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms)
US10064818B2 (en) * 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
RU2567829C1 (ru) * 2014-10-22 2015-11-10 Елизавета Геннадьевна Полунина Способ оценки морфофункционального состояния мейбомиевых желез - биометрия мейбомиевых желез
US12653779B2 (en) 2015-06-18 2026-06-16 Lenz Therapeutics Operations, Inc. Compositions and methods for the treatment of presbyopia
KR101714710B1 (ko) 2015-09-17 2017-03-10 고려대학교 산학협력단 마이봄샘 압출기
WO2017178892A2 (en) 2016-04-14 2017-10-19 M.G. Therapeutics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
WO2023091439A1 (en) 2021-11-17 2023-05-25 Lenz Therapeutics, Inc. Aceclidine derivatives, compositions thereof and methods of use thereof
CN116183427A (zh) * 2021-11-29 2023-05-30 巴西石油公司 用于评估延迟焦化装置的炉的管中的沉积的系统和方法
US11648247B1 (en) 2021-12-16 2023-05-16 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
DE3372965D1 (en) 1982-07-23 1987-09-17 Ici Plc Amide derivatives
US20050038110A1 (en) 2000-08-24 2005-02-17 Steiner Mitchell S. Selective androgen receptor modulators and methods of use thereof
US7645898B2 (en) 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US20040260108A1 (en) 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US8445534B2 (en) 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US20070173546A1 (en) 2000-08-24 2007-07-26 Dalton James T Selective androgen receptor modulators and method of use thereof
US6998500B2 (en) 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
IL154425A0 (en) 2000-08-24 2003-09-17 Univ Tennessee Res H Corp Selective androgen receptor modulators and methods of use thereof
US6838484B2 (en) 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
US7855229B2 (en) 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
WO2002022585A1 (en) 2000-09-14 2002-03-21 Kaken Pharmaceutical Co., Ltd. Tetrahydroquinoline compounds
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20070066568A1 (en) * 2005-08-31 2007-03-22 Dalton James T Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
US20070161608A1 (en) 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
HRP20040818A2 (en) 2002-02-28 2005-02-28 University Of Tennessee Research Foundation Haloacetamide and azide substituted compounds and methods of use thereof
US7803970B2 (en) 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
WO2003074449A2 (en) 2002-02-28 2003-09-12 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
JP5113979B2 (ja) 2002-02-28 2013-01-09 ユニバーシティ オブ テネシー リサーチ ファウンデーション 複数置換の選択的アンドロゲンレセプタ修飾因子及びその使用方法
AU2003241583B2 (en) 2002-06-17 2009-05-21 University Of Tennessee Research Foundation N-bridged selective androgen receptor modulators and methods of use thereof
US20040265916A1 (en) 2002-10-15 2004-12-30 Dalton James T. Method for detecting selective androgen receptor modulators
EP1562594A4 (en) 2002-10-15 2008-12-17 Univ Tennessee Res Foundation SELECTIVE ANDROGEN RECEPTOR MODULATORS WITH METHYLENE BRIDGES AND METHOD OF USE THEREOF
AU2003287075A1 (en) 2002-10-15 2004-05-04 Gtx, Inc. Treating obesity with selective androgen receptor modulators
US20040197928A1 (en) 2002-10-15 2004-10-07 Dalton James T. Method for detecting selective androgen receptor modulators
JP2006518328A (ja) 2002-10-15 2006-08-10 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション 複素環選択的アンドロゲン受容体調節剤及びその使用方法
US20060276539A1 (en) 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
CN1726020A (zh) 2002-10-16 2006-01-25 Gtx公司 用sarm治疗老年男性雄激素缺乏(adam)相关的疾病
US20040087810A1 (en) 2002-10-23 2004-05-06 Dalton James T. Irreversible selective androgen receptor modulators and methods of use thereof
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
EP2457892A1 (en) 2003-01-13 2012-05-30 University of Tennessee Research Foundation Large-scale synthesis of selective androgen receptor modulators
EP1594490A4 (en) 2003-01-22 2006-03-22 Gtx Inc TREATMENT OF WOMEN ANDROGEN DISEASE ASSOCIATED DISORDERS (ADIF) USING ANDROGENIC RECEPTOR MODULATORS (SARM)
AU2004305061A1 (en) * 2003-12-16 2005-07-07 Gtx, Inc. Prodrugs of selective androgen receptor modulators and methods of use thereof
JP2007517893A (ja) * 2004-01-10 2007-07-05 バイオリピッド インコーポレイテッド 脂質組成物及び該脂質組成物の使用方法
US20130034562A1 (en) 2004-06-07 2013-02-07 Dalton James T Selective androgen receptor modulators for treating diabetes
DK2289872T3 (en) 2004-06-07 2017-10-09 Univ Tennessee Res Found Medical use of a selective androgen receptor modulator
US20110237664A1 (en) 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
JP4899625B2 (ja) * 2006-05-12 2012-03-21 スズキ株式会社 鞍乗型不整地走行車両
ES2780193T3 (es) 2006-07-12 2020-08-24 Univ Tennessee Res Found Compuesto para tratar el cáncer de mama y afecciones dependientes de la progestina
WO2008011072A2 (en) 2006-07-19 2008-01-24 Osurf (Ohio State University Research Foundation) Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
AU2007287070C1 (en) 2006-08-24 2013-02-14 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
US20080312194A1 (en) * 2007-02-28 2008-12-18 Ousler Iii George W Methods and compositions for normalizing meibomian gland secretions
CA2886498C (en) 2007-09-11 2017-09-26 Gtx, Inc. Solid forms of selective androgen receptor modulators
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
HRP20150097T1 (hr) * 2008-05-07 2015-03-27 The Regents Of The University Of California Terapijska nadopuna i poboljšanje vlaženja površine oka

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9216028B2 (en) 2005-07-18 2015-12-22 Tearscience, Inc. Apparatuses for treatment of meibomian glands
US9913678B2 (en) 2005-07-18 2018-03-13 Tearscience, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
US8628504B2 (en) 2005-07-18 2014-01-14 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction employing fluid jet
US10940074B2 (en) 2005-07-18 2021-03-09 Tearscience Inc Melting meibomian gland obstructions
US8685073B2 (en) 2005-07-18 2014-04-01 Tearscience, Inc. Apparatus for treating meibomian gland dysfunction
US8915253B2 (en) 2005-07-18 2014-12-23 Tearscience, Inc. Method and apparatus for treating gland dysfunction employing heated medium
US10905898B2 (en) 2005-07-18 2021-02-02 Tearscience, Inc. Methods and apparatuses for treating gland dysfunction
US9060843B2 (en) 2005-07-18 2015-06-23 Tearscience, Inc. Method and apparatus for treating gland dysfunction employing heated medium
US10376273B2 (en) 2005-07-18 2019-08-13 Tearscience, Inc. Methods and apparatuses for treatment of meibomian glands
US9719977B2 (en) 2005-07-18 2017-08-01 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
US8523928B2 (en) 2006-05-15 2013-09-03 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8617229B2 (en) 2006-05-15 2013-12-31 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US8632578B2 (en) 2006-05-15 2014-01-21 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US10952896B2 (en) 2006-05-15 2021-03-23 Tearscience Inc Methods and apparatuses for treatment of meibomian gland dysfunction
US10842670B2 (en) 2012-08-22 2020-11-24 Johnson & Johnson Vision Care, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices

Also Published As

Publication number Publication date
EP2523556A4 (en) 2013-08-28
AU2011203832A1 (en) 2012-08-23
RU2012134351A (ru) 2014-02-20
CN103002737A (zh) 2013-03-27
US20110172302A1 (en) 2011-07-14
MX2012008110A (es) 2012-10-03
JP2013516501A (ja) 2013-05-13
EP2523556A1 (en) 2012-11-21
KR20120115380A (ko) 2012-10-17
WO2011085385A1 (en) 2011-07-14
US8791158B2 (en) 2014-07-29

Similar Documents

Publication Publication Date Title
US8791158B2 (en) Methods of treating meibomian gland dysfunction
JP7656589B2 (ja) エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体を用いて乳癌を治療する方法
EP3078376B1 (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
CN101299920A (zh) 用选择性雄激素受体调节剂治疗肾病、烧伤、创伤和脊髓损伤
CN102781436A (zh) 纤维肌痛综合征的治疗方法
JP2018521126A5 (enExample)
CN107531753A (zh) 吡咯烷酰胺衍生物及其制备和使用方法
JP2017531012A (ja) Sarmを使用した泌尿器系障害の治療方法
JP2016513706A (ja) 点眼用製剤
CA2674144A1 (en) Isosorbide mononitrate derivatives for the treatment of ocular hypertension
AU2022244467A1 (en) 1,3-substituted cyclobutyl derivatives and uses thereof
RU2672057C2 (ru) Ингибитор хориоретинальных нарушений
JP2011515406A (ja) 治療用の置換シクロペンタン類
JP2025514548A (ja) カレバスチンの塩及びその用途
US20200030305A1 (en) Local anesthetic-containing acidic emulsion composition
JP2017534658A (ja) プロスタグランジンと一酸化窒素供与体との組み合わせ
JP6588475B2 (ja) 治療用化合物としての新規のep4アゴニスト
JP2005047909A (ja) ピペリジン誘導体を有効成分とする掻痒治療剤
US11351136B2 (en) Compositions and methods for treating retinopathy
US20230174510A1 (en) N-acetylserotonin Derivatives as TrkB Activators and Uses Thereof
JP2018534358A (ja) Vegf阻害剤の局所投与による皮膚障害の処置
WO2025171323A1 (en) Compositions and methods for treating eye conditions
EP4136079A1 (en) Benzimidazole compound for the treatment of metabolic disorders
NZ522249A (en) Felbamate derived compounds
WO2017082393A1 (ja) 緑内障予防治療剤

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160112